Sborov, D. W., Canella, A., Hade, E. M., Mo, X., Khountham, S., Wang, J., . . . Hofmeister, C. C. (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma.
Styl ChicagoSborov, Douglas W., et al. "A Phase 1 Trial of the HDAC Inhibitor AR-42 in Patients With Multiple Myeloma and T- and B-cell Lymphomas." Leuk Lymphoma 2017.
Citace podle MLASborov, Douglas W., et al. "A Phase 1 Trial of the HDAC Inhibitor AR-42 in Patients With Multiple Myeloma and T- and B-cell Lymphomas." Leuk Lymphoma 2017.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..